

We are finding ourselves in the midst of a cardiometabolic renaissance.
Innovators face unique complexity as they must navigate interdependencies between different indications exhibited as co-morbidities in overlapping patient populations, who are treated by multiple HCP specialties.
This white paper explores what commercial excellence looks like for cardiometabolic innovation and how to achieve it.